Added value of CE-CT radiomics to predict high Ki-67 expression in hepatocellular carcinoma

被引:2
|
作者
Zhao, Yu-meng [1 ]
Xie, Shuang-shuang [2 ]
Wang, Jian [3 ]
Zhang, Ya-min [3 ]
Li, Wen-Cui [4 ]
Ye, Zhao-Xiang [4 ]
Shen, Wen [2 ]
机构
[1] Nankai Univ, Med Sch, 94 Weijin Rd, Tianjin, Peoples R China
[2] Nankai Univ, Tianjin Ctr Hosp 1, Sch Med, Dept Radiol,Tianjin Inst Imaging Med, 24 Fukang Rd, Tianjin, Peoples R China
[3] Nankai Univ, Tianjin Cent Hosp 1, Sch Med, Dept Hepatobiliary Surg, 24 Fukang Rd, Tianjin, Peoples R China
[4] Tianjin Med Univ, Natl Clin Res Ctr Canc, Dept Radiol, Canc Inst & Hosp, Tianjin 300060, Peoples R China
关键词
Hepatocellular carcinoma; Ki-67; expression; Contrast-enhanced computed tomography; Radiomics; DTPA-ENHANCED MRI; TEXTURE ANALYSIS; LIVER-CANCER; INVASION; NOMOGRAM; INDEX; STAGE;
D O I
10.1186/s12880-023-01069-4
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
BackgroundThis study aimed to develop a computed tomography (CT) model to predict Ki-67 expression in hepatocellular carcinoma (HCC) and to examine the added value of radiomics to clinico-radiological features.MethodsA total of 208 patients (training set, n = 120; internal test set, n = 51; external validation set, n = 37) with pathologically confirmed HCC who underwent contrast-enhanced CT (CE-CT) within 1 month before surgery were retrospectively included from January 2014 to September 2021. Radiomics features were extracted and selected from three phases of CE-CT images, least absolute shrinkage and selection operator regression (LASSO) was used to select features, and the rad-score was calculated. CE-CT imaging and clinical features were selected using univariate and multivariate analyses, respectively. Three prediction models, including clinic-radiologic (CR) model, rad-score (R) model, and clinic-radiologic-radiomic (CRR) model, were developed and validated using logistic regression analysis. The performance of different models for predicting Ki-67 expression was evaluated using the area under the receiver operating characteristic curve (AUROC) and decision curve analysis (DCA).ResultsHCCs with high Ki-67 expression were more likely to have high serum & alpha;-fetoprotein levels (P = 0.041, odds ratio [OR] 2.54, 95% confidence interval [CI]: 1.04-6.21), non-rim arterial phase hyperenhancement (P = 0.001, OR 15.13, 95% CI 2.87-79.76), portal vein tumor thrombus (P = 0.035, OR 3.19, 95% CI: 1.08-9.37), and two-trait predictor of venous invasion (P = 0.026, OR 14.04, 95% CI: 1.39-144.32). The CR model achieved relatively good and stable performance compared with the R model (AUC, 0.805 [95% CI: 0.683-0.926] vs. 0.678 [95% CI: 0.536-0.839], P = 0.211; and 0.805 [95% CI: 0.657-0.953] vs. 0.667 [95% CI: 0.495-0.839], P = 0.135) in the internal and external validation sets. After combining the CR model with the R model, the AUC of the CRR model increased to 0.903 (95% CI: 0.849-0.956) in the training set, which was significantly higher than that of the CR model (P = 0.0148). However, no significant differences were found between the CRR and CR models in the internal and external validation sets (P = 0.264 and P = 0.084, respectively).ConclusionsPreoperative models based on clinical and CE-CT imaging features can be used to predict HCC with high Ki-67 expression accurately. However, radiomics cannot provide added value.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue
    Kim, Seok Jin
    Shin, Hye Jin
    Jung, Kwang-Yoon
    Baek, Seung-Kuk
    Shin, Bong Kyung
    Choi, Jungwoo
    Kim, Byung Soo
    Shin, Sang Won
    Kim, Yeul Hong
    Kim, Jun Suk
    Oosterwijk, Egbert
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (11) : 812 - 819
  • [42] Prognostic and clinicopathological value of Ki-67 expression in patients with nasopharyngeal carcinoma: a meta-analysis
    Shi, Zhaohui
    Jiang, Weihong
    Chen, Xiaodong
    Xu, Min
    Wang, Xiaocheng
    Zha, Dingjun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [43] The expression of topoisomerase II α and Ki-67 in the gastric carcinoma.
    Rew, JS
    Koo, C
    Kim, HS
    Choi, SK
    Park, CS
    Kim, SJ
    GASTROENTEROLOGY, 1998, 114 (04) : A666 - A666
  • [44] Correlation Between Diagnostic Value of Diffusion Kurtosis Imaging for Nasopharyngeal Carcinoma and Ki-67 Expression
    Wu, Yingning
    Huang, Lina
    Li, Baosheng
    Li, Hengguo
    B-ENT, 2023, 19 (02) : 69 - 73
  • [45] Dual-energy CT in predicting Ki-67 expression in laryngeal squamous cell carcinoma
    Wang, Peng
    Tang, Zuohua
    Xiao, Zebin
    Wu, Lingjie
    Hong, Rujian
    Duan, Fei
    Wang, Yuzhe
    Zhan, Yang
    EUROPEAN JOURNAL OF RADIOLOGY, 2021, 140
  • [46] The expression of Ki-67 and Glypican-3 in hepatocellular carcinoma was evaluated by comparing DWI and 18F-FDG PET/CT
    Wang, Xuedong
    Li, Lei
    Wang, Linjie
    Chen, Min
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [47] Radiomics nomogram based on CT radiomics features and clinical factors for prediction of Ki-67 expression and prognosis in clear cell renal cell carcinoma: a two-center study
    Li, Ben
    Zhu, Jie
    Wang, Yanmei
    Xu, Yuchao
    Gao, Zhaisong
    Shi, Hailei
    Nie, Pei
    Zhang, Ju
    Zhuang, Yuan
    Wang, Zhenguang
    Yang, Guangjie
    CANCER IMAGING, 2024, 24 (01)
  • [48] Prognostic value of Ki-67 in nasopharyngeal carcinoma: a meta-analysis
    Li, Yulin
    Yue, Liang
    Li, Yanqing
    Zhang, Qinxiu
    Liang, Xin
    BIOSCIENCE REPORTS, 2021, 41 (05)
  • [49] Potential value of novel multiparametric MRI radiomics for preoperative prediction of microsatellite instability and Ki-67 expression in endometrial cancer
    Wang, Zhichao
    Hu, Yan
    Cai, Jun
    Xie, Jinyuan
    Li, Chao
    Wu, Xiandong
    Li, Jingjing
    Luo, Haifeng
    He, Chuchu
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [50] CT-based radiomics for predicting Ki-67 expression in lung cancer: a systematic review and meta-analysis
    Luo, Xinmin
    Zheng, Renying
    Zhang, Jiao
    He, Juan
    Luo, Wei
    Jiang, Zhi
    Li, Qiang
    FRONTIERS IN ONCOLOGY, 2024, 14